Hereditary Angioedema with Normal C1 Inhibitor

Immunology and Allergy Clinics of North America

Volumn 33, Issue 4, 2013, Pages 457-470

  Bork, Konrad ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Coagulation factor XII; Hereditary angioedema type III; Hereditary angioedema with normal C1 inhibitor; Kallikrein kinin pathway; Mutations in the F12 gene

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHISTAMINIC AGENT; ARGININE; BLOOD CLOTTING FACTOR 12; CAPTOPRIL; COMPLEMENT COMPONENT C1S INHIBITOR; CORTICOSTEROID; DANAZOL; DESOGESTREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ESTROGEN; ETONOGESTREL; HYDROCHLOROTHIAZIDE; ICATIBANT; LYSINE; MEDROXYPROGESTERONE; METOPROLOL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; THREONINE; TRANEXAMIC ACID;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ALLERGY; AMINO ACID SUBSTITUTION; ANGIONEUROTIC EDEMA; AUTOSOMAL DOMINANT INHERITANCE; CLINICAL FEATURE; COMPLEMENT BLOOD LEVEL; COMPLEMENT DEFICIENCY; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REDUCTION; EDEMA; FAMILY STUDY; GENE; GENE MUTATION; HAGEMAN FACTOR GENE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; LARYNX EDEMA; MORTALITY; PREGNANCY; PRIORITY JOURNAL; REVIEW; SEX RATIO; SKIN EDEMA; SUFFOCATION; TONGUE EDEMA; UPPER RESPIRATORY TRACT OBSTRUCTION; URTICARIA;

COAGULATION FACTOR XII; HEREDITARY ANGIOEDEMA TYPE III; HEREDITARY ANGIOEDEMA WITH NORMAL C1 INHIBITOR; KALLIKREIN-KININ PATHWAY; MUTATIONS IN THE F12 GENE;

ANGIOEDEMA; ANGIOEDEMAS, HEREDITARY; COMPLEMENT C1 INHIBITOR PROTEIN; DIAGNOSIS, DIFFERENTIAL; FACTOR XII; FEMALE; HUMANS; MALE; MUTATION; PREGNANCY; RISK FACTORS;

EID: 84886729872     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2013.07.002     Document Type: Review

References (38)

1. Bork K., Barnstedt S.E., Koch P., et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000, 356:213-217.
2. Binkley K.E., Davis A. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. JAllergy Clin Immunol 2000, 106:546-550.
3. Martin L., Degenne D., Toutain A., et al. Hereditary angioedema type III: an additional French pedigree with autosomal dominant transmission. JAllergy Clin Immunol 2001, 107:747-748.
4. Zuraw B.L., Bork K., Binkley K.E., et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc 2012, 33(Suppl 1):S145-S156.
5. Dewald G., Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006, 343:1286-1289.
6. Bork K., Wulff K., Meinke P., et al. Anovel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. Clin Immunol 2011, 141:31-35.
7. Bork K., Wulff K., Hardt J., et al. Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. JAllergy Clin Immunol 2009, 124:129-134.
8. Bork K., Gul D., Hardt J., et al. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med 2007, 120:987-992.
9. Bork K., Fischer B., Dewald G. Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am J Med 2003, 114:294-298.
10. Binkley K.E., Davis A.E. Estrogen-dependent inherited angioedema. Transfus Apher Sci 2003, 29:215-219.
11. Sabroe R.A., Black A.K. Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol 1997, 136:153-158.
12. Vleeming W., van Amsterdam J.G., Stricker B.H., et al. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf 1998, 18:171-188.
13. Agostoni A., Cicardi M. Contraindications to the use of ace inhibitors in patients with C1 esterase inhibitor deficiency. Am J Med 1991, 90:278.
14. Bork K., Gul D., Dewald G. Hereditary angio-oedema with normal C1 inhibitor in a family with affected women and men. Br J Dermatol 2006, 154:542-545.
15. Bork K., Dewald G. Hereditary angioedema type III, angioedema associated with angiotensin II receptor antagonists, and female sex. Am J Med 2004, 116:644-645.
16. Martin L., Raison-Peyron N., Nothen M.M., et al. Hereditary angioedema with normal C1 inhibitor gene in a family with affected women and men is associated with the p.Thr328Lys mutation in the F12 gene. JAllergy Clin Immunol 2007, 120:975-977.
17. Marcos C., Lopez Lera A., Varela S., et al. Clinical, biochemical, and genetic characterization of type III hereditary angioedema in 13 Northwest Spanish families. Ann Allergy Asthma Immunol 2012, 109:195-200.e2.
18. Cichon S., Martin L., Hennies H.C., et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006, 79:1098-1104.
19. Bouillet L., Ponard D., Rousset H., et al. Acase of hereditary angio-oedema type III presenting with C1-inhibitor cleavage and a missense mutation in the F12 gene. Br J Dermatol 2007, 156:1063-1065.
20. Bell C.G., Kwan E., Nolan R.C., et al. First molecular confirmation of an Australian case of type III hereditary angioedema. Pathology 2008, 40:82-83.
21. Prieto A., Tornero P., Rubio M., et al. Missense mutation Thr309Lys in the coagulation factor XII gene in a Spanish family with hereditary angioedema type III. Allergy 2009, 64:284-286.
22. Duan Q.L., Binkley K., Rouleau G.A. Genetic analysis of Factor XII and bradykinin catabolic enzymes in a family with estrogen-dependent inherited angioedema. JAllergy Clin Immunol 2009, 123:906-910.
23. Nagy N., Greaves M.W., Tanaka A., et al. Recurrent European missense mutation in the F12 gene in a British family with type III hereditary angioedema. JDermatol Sci 2009, 56:62-64.
24. Hentges F., Hilger C., Kohnen M., et al. Angioedema and estrogen-dependent angioedema with activation of the contact system. JAllergy Clin Immunol 2009, 123:262-264.
25. Picone O., Donnadieu A.C., Brivet F.G., et al. Obstetrical complications and outcome in two families with hereditary angioedema due to mutation in the F12 gene. Obstet Gynecol Int 2010, 2010:957507.
26. Vitrat-Hincky V., Gompel A., Dumestre-Perard C., et al. Type III hereditary angio-oedema: clinical and biological features in a French cohort. Allergy 2010, 65:1331-1336.
27. Baeza M.L., Rodriguez-Marco A., Prieto A., et al. Factor XII gene missense mutation Thr328Lys in an Arab family with hereditary angioedema type III. Allergy 2011, 66:981-982.
28. Kaplan A.P., Joseph K., Shibayama Y., et al. The intrinsic coagulation/kinin-forming cascade: assembly in plasma and cell surfaces in inflammation. Adv Immunol 1997, 66:225-272.
29. Cool D.E., MacGillivray R.T. Characterization of the human blood coagulation factor XII gene. Intron/exon gene organization and analysis of the 5'-flanking region. JBiol Chem 1987, 262:13662-13673.
30. Cool D.E., Edgell C.J., Louie G.V., et al. Characterization of human blood coagulation factor XII cDNA. Prediction of the primary structure of factor XII and the tertiary structure of beta-factor XIIa. JBiol Chem 1985, 260:13666-13676.
31. Citarella F., Aiuti A., La Porta C., et al. Control of human coagulation by recombinant serine proteases. Blood clotting is activated by recombinant factor XII deleted of five regulatory domains. Eur J Biochem 1992, 208:23-30.
32. Citarella F., Ravon D.M., Pascucci B., et al. Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces. Eur J Biochem 1996, 238:240-249.
33. Bork K., Kleist R., Hardt J., et al. Kallikrein-kinin system and fibrinolysis in hereditary angioedema due to the factor XII gene mutation Thr309Lys. Blood Coagul Fibrinolysis 2009, 20:325-332.
34. Bouillet L., Boccon-Gibod I., Ponard D., et al. Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. Ann Allergy Asthma Immunol 2009, 103:448.
35. Boccon-Gibod I., Bouillet L. Safety and efficacy of icatibant self-administration for acute hereditary angioedema. Clin Exp Immunol 2012, 168:303-307.
36. Serrano C., Guilarte M., Tella R., et al. Oestrogen-dependent hereditary angio-oedema with normal C1 inhibitor: description of six new cases and review of pathogenic mechanisms and treatment. Allergy 2008, 63:735-741.
37. Herrmann G., Schneider L., Krieg T., et al. Efficacy of danazol treatment in a patient with the new variant of hereditary angio-oedema (HAE III). Br J Dermatol 2004, 150:157-158.
38. Bork K. Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. Immunol Allergy Clin North Am 2006, 26:709-724.